275 completed, 30 terminated, 19 unknown, 13 withdrawn. 99 Phase 4, 97 Phase 3, 65 Phase 1, 44 Not applicable, 33 Phase 2.
Follow Insulin Aspart: new trials by email Literature Review of Insulin Aspart trials Research Report on Insulin Aspart
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart GZR101 80 Injection, GZR33 Injection, Insulin Aspart Injection - Healthy Participants | Phase 1 | Recruiting | Gan & Lee Pharmaceuticals. | 26 | 2026-11-02 | 2026-11-17 |
| CGM-guided Patch Pump vs Basal-Bolus Injection for Steroid-Induced Hyperglycemia in Sudden Sensorineural Hearing Loss: SHIP Trial CareLevo Patch-type Insulin Pump, Insulin Glargine U-100 (Lantus), Fast-acting Insulin Aspart (Fiasp) - Sudden Sensorineural Hearing Loss (SSNHL), Prediabetes / Type 2 Diabetes | Not applicable | Not yet recruiting | Hallym University | 50 | 2026-08-01 | 2026-07-22 |
| Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes GZR101-80, GZR33 or Insulin degludec/Insulin aspart or Insulin aspart30 (NovoRapid®30) - Type 2 Diabetes (T2DM) | Phase 2 | Not yet recruiting | Gan & Lee Pharmaceuticals. | 345 | 2026-04-10 | 2026-04-15 |
| Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers I004, NovoLog - Pharmacokinetics, Pharmacodynamics | Phase 2 / Phase 3 | Completed | Amphastar Pharmaceuticals, Inc. | 62 | 2026-04-06 | 2026-07-22 |
| A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes Insulin icodec, Insulin glargine, Insulin aspart - Diabetes Mellitus, Type 1 | Phase 3 | Active not recruiting | Novo Nordisk A/S | 877 | 2025-08-11 | 2026-09-25 |
| A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 2 Diabetes When Given by an Insulin Pump NNC0471-0119 H, Insulin Aspart - Diabetes Mellitus, Type 2 | Phase 1 | Completed | Novo Nordisk A/S | 65 | 2025-07-11 | 2026-04-07 |
| A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 1 Diabetes When Given by an Insulin Pump NNC0471-0119 H, Insulin aspart - Diabetes Mellitus, Type 1 | Phase 1 | Completed | Novo Nordisk A/S | 43 | 2025-01-29 | 2026-09-10 |
| Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM Insulin aspart - Gestational Diabetes, Endothelial Dysfunction | Early Phase 1 | Recruiting | Anna Stanhewicz, PhD | 40 | 2024-10-01 | 2026-10-29 |
| A Trial of Three- and Seven-days Insulin Infusions Set Mio Advanced infusions set, Novorapid, Extended wear insulin infusion (EWIS) - Type 1 Diabetes | Not applicable | Recruiting | Steno Diabetes Center Copenhagen | 80 | 2024-07-20 | 2024-08-06 |
| A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection OD GZR101 Injection, GZR33 Injection, Insulin aspart - Type 2 Diabetes | Phase 2 | Unknown | Gan and Lee Pharmaceuticals, USA | 60 | 2024-06-28 | 2024-08-19 |
| Comparison of HR011408 and NovoRapid® in Subjects With Diabetics HR011408 injection; HR011408 injection Placebo, NovoRapid®; HR011408 injection Placebo, HR011408 injection Placebo; HR011408 injection - Diabetes | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 30 | 2024-05-01 | 2024-05-21 |
| A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM GZR101, insulin degledec/insulin aspart - Type 2 Diabetes | Phase 2 | Completed | Gan and Lee Pharmaceuticals, USA | 153 | 2023-11-21 | 2025-01-17 |
| Role of NADPH Oxidase in Microvascular Dysfunction Following GDM Acetylcholine, Insulin aspart - Gestational Diabetes, Oxidative Stress | Early Phase 1 | Active not recruiting | Anna Stanhewicz, PhD | 40 | 2023-08-30 | 2026-07-29 |
| Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes Acetylcholine, insulin aspart - Gestational Diabetes, Vascular Endothelial Function | Early Phase 1 | Recruiting | Anna Stanhewicz, PhD | 28 | 2023-07-01 | 2026-07-29 |
| Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM Insulin Degludec and Insulin Aspart Injection, Insulin Aspart Injection - Type 2 Diabetes Mellitus | Not applicable | Completed | Beijing Hospital | 218 | 2023-03-23 | 2025-12-03 |
| The Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid® in Healthy Subject HR011408 injection; NovoRapid®, NovoRapid®;HR011408 injection - Diabetes | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 61 | 2023-03-20 | 2024-02-07 |
| The Effect of Short-term Insulin Intensive Therapy Based on the Application of Insulin Pump and Real-time Dynamic Glucose Monitoring Technology on Reversing the Newly Diagnosed Type 2 Diabetes Insulin Glargine, Metformin, Dapagliflozin - Insulin Pump,Continuous Glucose Monitoring Technology | Phase 4 | Unknown | Sun Yat-sen University | 210 | 2023-03-07 | 2023-11-13 |
| AT278, NovoRapid® and Humulin® R (U500) in Glucose Clamp Study AT278, NovoRapid, Humulin R 500 UNT/ML Injectable Solution - Diabetes Mellitus, Type 2 | Phase 1 | Completed | Arecor Limited | 41 | 2023-02-27 | 2024-02-16 |
| Bioequivalence Study of INS062 and Pharmacokinetics and Pharmacokinetics Study of Single Injection of HR20014 in Healthy Subjects INS062 injection, Insulin Aspart, HR20014 injection - Diabetes | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 60 | 2023-01-05 | 2023-02-09 |
| Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers I004, NovoLog - Pharmacokinetics, Pharmacodynamics | Phase 2 / Phase 3 | Completed | Amphastar Pharmaceuticals, Inc. | 69 | 2022-08-22 | 2026-03-05 |
Showing 20 of 349. Sign in to see all of them.
Diabetes Mellitus (191) · Diabetes Mellitus, Type 1 (168) · Diabetes Mellitus, Type 2 (117) · Insulin Resistance (33) · Hypoglycemia (22) · Hyperglycemia (20) · Diabetes Complications (10) · Diabetes, Gestational (8) · Alzheimer Disease (3) · Atherosclerosis (3) · Cystic Fibrosis (2) · Diabetic Neuropathies (2) · Endocrine System Diseases (2) · Glucose Intolerance (2) · Glucose Metabolism Disorders (2)
Novo Nordisk A/S (141) · Emory University (13) · Florida Atlantic University (11) · Sanofi (11) · Halozyme Therapeutics (6) · Medical University of Warsaw (6) · University of Aarhus (5) · Albert Einstein College of Medicine (4) · Arecor Limited (4) · Eli Lilly and Company (4) · Karolinska Institutet (4) · Mannkind Corporation (4) · Medical University of Graz (4) · Anna Stanhewicz, PhD (3) · Institut de Recherches Cliniques de Montreal (3)
United States (135) · Germany (66) · France (34) · Russia (33) · Denmark (29) · United Kingdom (29) · Austria (28) · Poland (26) · Canada (24) · Spain (21) · China (19) · Finland (18) · India (18) · Italy (17) · Japan (17)
Betty Tuller, PhD (7) · Guillermo Umpierrez, MD (4) · Betty Tuller, Ph.D (3) · David Baldwin, MD (3) · Rubina A Heptulla, MD (3) · Agnieszka Szypowska (2) · Agnieszka Szypowska, Prof. (2) · Bruce Buckingham, MD (2)
PMID 28205039, PMID 30402720, PMID 23130654, PMID 24170235, PMID 26121451, PMID 26232910, PMID 26484727, PMID 35044568, PMID 24812526, PMID 25081590, PMID 28210866, PMID 28672316, PMID 29463670, PMID 30547388, PMID 36106652, PMID 37526194, PMID 40465144, PMID 41051694, PMID 42814374, PMID 10332663, PMID 11943004, PMID 12502678, PMID 15189754, PMID 15298338, PMID 15353407, PMID 15575341, PMID 16054266, PMID 16367883, PMID 16842476, PMID 17115349, PMID 17160407, PMID 17227321, PMID 17259511, PMID 17381500, PMID 17392539, PMID 17392541, PMID 17392542, PMID 17596485, PMID 17683100, PMID 17850471, PMID 17888133, PMID 17890232, PMID 17905178, PMID 17909083, PMID 17989308, PMID 18275357, PMID 18387078, PMID 18539917, PMID 18644065, PMID 18726086
2009 (8), 2005 (7), 2008 (7), 2014 (6), 2017 (6), 2015 (5), 2016 (4), 2004 (3), R01DK077166 (2), R01HL169201 (2), 1UC4DK108612-01 (1), F31HL177925 (1), K23DK124647 (1), K23HD103875 (1), N01HC95178 (1)